WO2012002775A3 - 뉴로필린１ 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법 - Google Patents

뉴로필린１ 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법 Download PDF

Info

Publication number
WO2012002775A3
WO2012002775A3 PCT/KR2011/004864 KR2011004864W WO2012002775A3 WO 2012002775 A3 WO2012002775 A3 WO 2012002775A3 KR 2011004864 W KR2011004864 W KR 2011004864W WO 2012002775 A3 WO2012002775 A3 WO 2012002775A3
Authority
WO
WIPO (PCT)
Prior art keywords
asthma
screening
neuropilin
gene
therapeutic agent
Prior art date
Application number
PCT/KR2011/004864
Other languages
English (en)
French (fr)
Other versions
WO2012002775A4 (ko
WO2012002775A2 (ko
Inventor
이형규
안경섭
윤유식
최병휘
권옥경
김세미
김희성
오세량
육지은
장하영
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Priority to US13/807,829 priority Critical patent/US9078912B2/en
Publication of WO2012002775A2 publication Critical patent/WO2012002775A2/ko
Publication of WO2012002775A3 publication Critical patent/WO2012002775A3/ko
Publication of WO2012002775A4 publication Critical patent/WO2012002775A4/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302—Apparatus specially adapted for immunological test procedures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

본 발명은 뉴로필린(Neuropilin, NRP) 유전자를 포함하는 천식 진단 및 스크리닝용 키트 및 이를 이용한 천식 치료제 스크리닝 방법에 관한 것으로서, 보다 구체적으로 천식 환자 및 집먼지진드기 추출물에 의해서 NRP1의 발현이 증가되며, NRP1의 발현 억제에 의해서 천식과 관련된 MMP9의 mRNA, 단백질 발현, 효소 활성 및 프로모터의 활성이 감소하는 결과를 통해서 NRP1을 천식 치료제 개발을 위한 표적으로서 유용하게 사용될 수 있음을 확인하였다.
PCT/KR2011/004864 2010-07-02 2011-07-01 뉴로필린１ 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법 WO2012002775A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/807,829 US9078912B2 (en) 2010-07-02 2011-07-01 Asthma diagnosis using the neuropilin-1 gene, and method for screening for a therapeutic agent for asthma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100063905A KR20120003187A (ko) 2010-07-02 2010-07-02 Ｎｅｕｒｏｐｉｌｉｎ １ 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법
KR10-2010-0063905 2010-07-02

Publications (3)

Publication Number Publication Date
WO2012002775A2 WO2012002775A2 (ko) 2012-01-05
WO2012002775A3 true WO2012002775A3 (ko) 2012-04-12
WO2012002775A4 WO2012002775A4 (ko) 2012-06-14

Family

ID=45402606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/004864 WO2012002775A2 (ko) 2010-07-02 2011-07-01 뉴로필린１ 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법

Country Status (3)

Country Link
US (1) US9078912B2 (ko)
KR (1) KR20120003187A (ko)
WO (1) WO2012002775A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014058915A2 (en) 2012-10-08 2014-04-17 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1221618A1 (en) * 2000-11-29 2002-07-10 GeneScan Europe AG Method for diagnosing allergic diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417169B1 (en) * 1998-04-23 2002-07-09 Genesense Technologies Inc. Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2010054221A2 (en) * 2008-11-06 2010-05-14 The Johns Hopkins University Treatment of chronic inflammatory respiratory disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1221618A1 (en) * 2000-11-29 2002-07-10 GeneScan Europe AG Method for diagnosing allergic diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRUDER, D. ET AL.: "Neuropilin-1: a surface marker of regulatory T cells", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 34, no. 3, March 2004 (2004-03-01), pages 623 - 630 *
DORSAM, G. P.: "Gene expression profiling and network analysis of peripheral blood monocytes in a chronic model of allergic asthma", MICROBIOLOGY AND IMMUNOLOGY., vol. 54, no. 9, September 2010 (2010-09-01), pages 558 - 563 *
GERETTI, E. ET AL.: "Neuropilins: Novel Targets for anti-angiogenesis therapies", CELL ADHESION AND MIGRATION., vol. 2, 25 April 2007 (2007-04-25), pages 56 - 61, XP002613735, DOI: doi:10.4161/cam.1.2.4490 *
KORF, J. E. ET AL.: "Macrophage reprogramming by mycolic acid promotes a tolerogenic response in experimental asthma", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE., vol. 174, no. 2, 4 May 2006 (2006-05-04), pages 152 - 160, XP002546341, DOI: doi:10.1164/RCCM.200507-1175OC *

Also Published As

Publication number Publication date
WO2012002775A4 (ko) 2012-06-14
WO2012002775A2 (ko) 2012-01-05
US9078912B2 (en) 2015-07-14
US20130108652A1 (en) 2013-05-02
KR20120003187A (ko) 2012-01-10

Similar Documents

Publication Publication Date Title
WO2012129084A3 (en) Glucosylceramide synthase inhibitors
PH12015501470A1 (en) Compositions and methods for the control of nematodes and soil borne diseases
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
WO2014028493A3 (en) Exosomes and micro-ribonucleic acids for tissue regeneration
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EA202091568A1 (ru) Ингибиторы глюкозилцерамид-синтазы
WO2011127070A3 (en) IRE-1α INHIBITORS
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2010141596A3 (en) Chemical proteomic assay for optimizing drug binding to target proteins
WO2011011366A3 (en) Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
WO2011106322A3 (en) Biomarkers for acute ischemic stroke
WO2009158031A3 (en) Methods and compositions for therapeutic treatment
ATE511645T1 (de) Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme
WO2014093051A3 (en) Cardiac stem cells and methods of identifying and using the same
IN2012DN06588A (ko)
WO2011146143A3 (en) Enzymatic activity of psa as diagnostic marker for prostate cancer
MX2012007873A (es) Promotor de reparacion del daño de acido desoxirribonucleico para aplicacion oral e inhibidor de la actividad de elastasa para apalicacion oral.
NZ616048A (en) Administration of iloprost as aerosol bolus
PH12014500990A1 (en) Methods for treating gout flares
MY186172A (en) Endogenous dnase activity to reduce dna content
WO2007067564A3 (en) Improved host cells and culture methods
WO2011106785A3 (en) Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
WO2007130575A3 (en) Protection against oxidative damage in cells
WO2015006501A3 (en) Microvessel endothelial cell surface markers and uses thereof
WO2011092694A3 (en) Method for improved fibrin sealing

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11801180

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13807829

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11801180

Country of ref document: EP

Kind code of ref document: A2